The cell and gene therapy contract development and manufacturing organization (cdmo) global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The cell and gene therapy contract development and manufacturing organization (CDMO) market size has grown exponentially in recent years. It will grow from $4.24 billion in 2023 to $5.41 billion in 2024 at a compound annual growth rate (CAGR) of 27.7%. The growth in the historic period can be attributed to increased technological advancements, favorable regulatory frameworks, increased investment, high prevalence of genetic disorders, and an increased number of strategic partnerships.
The cell and gene therapy contract development and manufacturing organization (CDMO) market size is expected to see exponential growth in the next few years. It will grow to $14.52 billion in 2028 at a compound annual growth rate (CAGR) of 28.0%. The growth in the forecast period can be attributed to expanded therapeutic applications, regulatory evolution, increased investment, technological innovations, and global collaboration. Major trends in the forecast period include increased demand for personalized therapies, growth in automation and digitalization, expansion of manufacturing capacities, emergence of novel delivery systems, and heightened focus on sustainability and environmental impact.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-contract-development-and-manufacturing-organization-cdmo-global-market-report
Scope Of Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Overview
Market Drivers –
The cell and gene therapy contract development and manufacturing organization (CDMO) market size has grown exponentially in recent years. It will grow from $4.24 billion in 2023 to $5.41 billion in 2024 at a compound annual growth rate (CAGR) of 27.7%. The growth in the historic period can be attributed to increased technological advancements, favorable regulatory frameworks, increased investment, high prevalence of genetic disorders, and an increased number of strategic partnerships.
The cell and gene therapy contract development and manufacturing organization (CDMO) market size is expected to see exponential growth in the next few years. It will grow to $14.52 billion in 2028 at a compound annual growth rate (CAGR) of 28.0%. The growth in the forecast period can be attributed to expanded therapeutic applications, regulatory evolution, increased investment, technological innovations, and global collaboration. Major trends in the forecast period include increased demand for personalized therapies, growth in automation and digitalization, expansion of manufacturing capacities, emergence of novel delivery systems, and heightened focus on sustainability and environmental impact.
Market Trends –
Major companies operating in the cell and gene therapy contract development and manufacturing organization (CDMO) market are focused on expanding their portfolio with advanced solutions such as PluriMatrix technology to enhance the scalability, efficiency, and quality of cell-based product manufacturing. PluriMatrix technology is a proprietary system tailored for the large-scale production of cell-based products. This advanced technology facilitates the 3D expansion of cells on an industrial scale, ensuring high yield and consistent quality through an automated, fully controlled, and validated process. For instance, in January 2024, Pluri, an Israel-based biotech company, launched PluriCDMO, a new business division that offers cell therapy manufacturing services as a contract development and manufacturing organization (CDMO). The new division includes a 47,000-square-foot good manufacturing practice (GMP) cell therapy production facility. Pluri’s newly established division offers end-to-end services from early preclinical stages to late-stage clinical trials and commercialization, covering process and analytical development, scale-up, validation, logistics, automation, and regulatory-approved comparability studies, as detailed in a company announcement. It leverages the company’s cutting-edge PluriMatrix technology to offer advanced cell therapy manufacturing services.
The cell and gene therapy contract development and manufacturing organization (CDMO) market covered in this report is segmented –
1) By Product Type: Gene Therapy, Gene-Modified Cell Therapy, Cell Therapy
2) By Phase: Phase 1, Phase 2, Phase 3, Phase 4
3) By Indication: Oncology, Infectious Diseases, Neurological Disorders, Rare Diseases, Other Indications
Get an inside scoop of the cell and gene therapy contract development and manufacturing organization (cdmo) market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=15753&type=smp
Regional Insights –
North America was the largest region in the cell and gene therapy contract development and manufacturing organization (CDMO) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy contract development and manufacturing organization (CDMO) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Key Companies –
Major companies operating in the cell and gene therapy contract development and manufacturing organization (CDMO) market are focused on expanding their portfolio with advanced solutions such as PluriMatrix technology to enhance the scalability, efficiency, and quality of cell-based product manufacturing. PluriMatrix technology is a proprietary system tailored for the large-scale production of cell-based products. This advanced technology facilitates the 3D expansion of cells on an industrial scale, ensuring high yield and consistent quality through an automated, fully controlled, and validated process. For instance, in January 2024, Pluri, an Israel-based biotech company, launched PluriCDMO, a new business division that offers cell therapy manufacturing services as a contract development and manufacturing organization (CDMO). The new division includes a 47,000-square-foot good manufacturing practice (GMP) cell therapy production facility. Pluri’s newly established division offers end-to-end services from early preclinical stages to late-stage clinical trials and commercialization, covering process and analytical development, scale-up, validation, logistics, automation, and regulatory-approved comparability studies, as detailed in a company announcement. It leverages the company’s cutting-edge PluriMatrix technology to offer advanced cell therapy manufacturing services.
Table of Contents
1. Executive Summary
2. Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Characteristics
3. Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Trends And Strategies
4. Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market – Macro Economic Scenario
5. Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Size and Growth
.
.
.
32. Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Competitive Benchmarking
33. Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market
35. Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
